Principal Investigator/Program Director (Last, first, middle): HAAS, ARTHUR, L RESEARCH &RELATED Other Project Information 1. * Are Human Subjects Involved? m Yes l No 1.a. If YES to Human Subjects Is the IRB review Pending? m Yes m No IRB Approval Date: Exemption Number: 1 2 3 4 5 6 Human Subject Assurance Number 2. * Are Vertebrate Animals Used? m Yes l No 2.a. If YES to Vertebrate Animals Is the IACUC review Pending? m Yes m No IACUC Approval Date: Animal Welfare Assurance Number 3. * Is proprietary/privileged information m Yes l No included in the application? 4.a.* Does this project have an actual or potential impact on m Yes l No the environment? 4.b. If yes, please explain: 4.c. If this project has an actual or potential impact on the environment, has an exemption been authorized or an environmental assessment (EA) or environmental impact statement (EIS) been performed? m Yes m No 4.d. If yes, please explain: 5.a.* Does this project involve activities outside the U.S. or m Yes l No partnership with International Collaborators? 5.b. If yes, identify countries: 5.c. Optional Explanation: 6. * Project Summary/Abstract 7249-Abstract.pdf Mime Type: application/pdf 7. * Project Narrative 8473-Gm34009-22_relevance.pdf Mime Type: application/pdf 8. Bibliography &References Cited 5469-Literature_Cited.pdf Mime Type: application/pdf 9. Facilities &Other Resources 9258-Resources-Facilities.pdf Mime Type: application/pdf 10. Equipment 1452-Resources-Major_Equipment.pdf Mime Type: application/pdf Tracking Number: Other Information Page 5 OMB Number: 4040-0001 Expiration Date: 04/30/2008 Principal Investigator/Program Director (Last, first, middle): HAAS, ARTHUR, L The ubiquitin/26S proteasome pathway is a fundamental strategy for eukaryotic cell regulation in which proteins are targeted for destruction by assembly on them of specific polyubiquitin degradation signals that are recognized by the 19S regulatory complex of the 26S proteasome. A super family of ubiquitin- like proteins that undergo parallel but distinct conjugation reactions have co-evolved to serve regulatory functions distinct from targeted degradation. The functional specificities of these post-translational modificationsrequirepreciselydirectedproteininteractionsamongcomponentsoftheligationmachinery. Duringthecurrentfundingperiodconventionalbiochemicalandgeneticapproacheshavebeenexploited inparttodefinetheseproteininteractionsathighresolution. Studiesproposedforthenextfundingperiod comprise three Specific Aims designed to build upon these advances.
Specific Aim 1 will use biochemical and genetic approaches to study E1-catalyzed activation of Class 1 ubiquitin-like proteins andwillexaminetheroleofthecarboxylterminal ?-graspdomainasaspecificityfilterforcognateE2/Ubc recognition, the role of ?-grasp domain versus Ubc12 amino-terminal peptide binding in transition state stabilization during Nedd8 activation, and characterize selected E1 residues in binding versus catalytic roles.
Specific Aim 2 will examine the mechanism of a novel subset of Bi-functional Ligases capable of modifying their cognate protein substrates with either ubiquitin to target degradation or the interferon- inducedISG15ubiquitin-likeproteintoblockdegradation. KineticstudieswillquantifytheabilityofUbcH7 (ubiquitin specific) and UbcH8 (ISG15 specific) to support Epf/Trim25 ligase in regulating levels of the anti-mitotic 14-3-3? protein implicated in breast and prostate cancers. Other studies will examine the consequences of ubiquitin versus ISG15 modification on the half life of 14-3-3?.
Specific Aim 3 will continue studies on the enzymology of Mdm2 and MdmX homo- and heterodimers as ubiquitin ligases. Kinetic studies will examine the mechanism of MdmX-stimulated Mdm2-dependent ubiquitination, test a two-

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MSFE-S (01))
Program Officer
Jones, Warren
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Louisiana State Univ Hsc New Orleans
Schools of Medicine
New Orleans
United States
Zip Code
Todaro, Dustin R; Augustus-Wallace, Allison C; Klein, Jennifer M et al. (2018) Oligomerization of the HECT ubiquitin ligase NEDD4-2/NEDD4L is essential for polyubiquitin chain assembly. J Biol Chem 293:18192-18206
Todaro, Dustin R; Augustus-Wallace, Allison C; Klein, Jennifer M et al. (2017) The mechanism of neural precursor cell expressed developmentally down-regulated 4-2 (Nedd4-2)/NEDD4L-catalyzed polyubiquitin chain assembly. J Biol Chem 292:19521-19536
Ronchi, Virginia P; Kim, Elizabeth D; Summa, Christopher M et al. (2017) In silico modeling of the cryptic E2?ubiquitin-binding site of E6-associated protein (E6AP)/UBE3A reveals the mechanism of polyubiquitin chain assembly. J Biol Chem 292:18006-18023
Edwards, Daniel J; Streich Jr, Frederick C; Ronchi, Virginia P et al. (2014) Convergent evolution in the assembly of polyubiquitin degradation signals by the Shigella flexneri IpaH9.8 ligase. J Biol Chem 289:34114-28
Ronchi, Virginia P; Klein, Jennifer M; Edwards, Daniel J et al. (2014) The active form of E6-associated protein (E6AP)/UBE3A ubiquitin ligase is an oligomer. J Biol Chem 289:1033-48
Streich Jr, Frederick C; Ronchi, Virginia P; Connick, J Patrick et al. (2013) Tripartite motif ligases catalyze polyubiquitin chain formation through a cooperative allosteric mechanism. J Biol Chem 288:8209-21
Ronchi, Virginia P; Klein, Jennifer M; Haas, Arthur L (2013) E6AP/UBE3A ubiquitin ligase harbors two E2~ubiquitin binding sites. J Biol Chem 288:10349-60
Ronchi, Virginia P; Haas, Arthur L (2012) Measuring rates of ubiquitin chain formation as a functional readout of ligase activity. Methods Mol Biol 832:197-218
Tokgöz, Zeynep; Siepmann, Thomas J; Streich Jr, Frederick et al. (2012) E1-E2 interactions in ubiquitin and Nedd8 ligation pathways. J Biol Chem 287:311-21
Kumar, Brajesh; Lecompte, Kimberly G; Klein, Jennifer M et al. (2010) Ser(120) of Ubc2/Rad6 regulates ubiquitin-dependent N-end rule targeting by E3{alpha}/Ubr1. J Biol Chem 285:41300-9

Showing the most recent 10 out of 57 publications